Press Release: BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

Dow Jones11-05
   --  Total global revenues of $1.9 billion for the third quarter, an 
      increase of 34% from the prior year 
 
   --  BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third 
      quarter, an increase of 34% from the prior year 
 
   --  Diluted GAAP Earnings per American Depository Share (ADS) of $3.28 for 
      the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the 
      third quarter 
 
   --  Raised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP 
      operating income of $1.2 to $1.3 billion, non-GAAP operating income of 
      $1.9 to $2.0 billion 
SAN CARLOS, Calif.--(BUSINESS WIRE)--November 05, 2026-- 

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026.

John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

"Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization."

 
(Amounts in thousands of U.S. dollars and unaudited) 
 
                 Three Months Ended                  Nine Months Ended 
                   September 30,                       September 30, 
               ----------------------              ---------------------- 
                  2026        2025      % Change      2026        2025      % Change 
               ----------  ----------  ----------  ----------  ----------  ---------- 
Net product 
 revenues      $1,855,057  $1,395,013    33%       $5,022,180  $3,805,619    32% 
Other revenue  $   34,758  $   17,271   101%       $   86,144  $   39,244   120% 
                ---------   ---------               ---------   --------- 
Total revenue  $1,889,815  $1,412,284    34%       $5,108,324  $3,844,863    33% 
 
GAAP income 
 from 
 operations    $  418,675  $  163,114   157%       $  993,624  $  262,101   279% 
Adjusted 
 income from 
 operations*   $  612,226  $  341,184    79%       $1,529,649  $  755,486   102% 
 
GAAP net 
 income        $  384,706  $  124,841   208%       $  849,070  $  220,431   285% 
Adjusted net 
 income*       $  538,735  $  303,663    77%       $1,358,274  $  692,622    96% 
 
GAAP basic 
 EPS per ADS   $     3.38  $     1.13   199%       $     7.58  $     2.03   273% 
Adjusted 
 basic EPS 
 per ADS*      $     4.74  $     2.76    72%       $    12.12  $     6.38    90% 
 
GAAP diluted 
 EPS per ADS   $     3.28  $     1.09   201%       $     7.30  $     1.96   272% 
Adjusted 
 diluted EPS 
 per ADS*      $     4.59  $     2.65    73%       $    11.68  $     6.14    90% 
 
Free Cash 
 Flow*         $  473,532  $  354,469    34%       $1,069,423  $  561,916    90% 
 
*For an explanation of our use of non-GAAP financial measures, refer to the "Note 
Regarding Use of Non-GAAP Financial Measures" section later in this press release and 
for a reconciliation of each non-GAAP financial measure to the most comparable GAAP 
measures, see the table at the end of this press release. 
 

Third Quarter 2026 Financial Results

Product Revenue totaled $1.9 billion for the third quarter of 2026, representing growth of 33% compared to the prior-year period.

   --  BRUKINSA: Global sales totaled $1.4 billion for the third quarter of 
      2026, representing growth of 34% compared to the prior-year period; U.S. 
      sales of BRUKINSA totaled $1.0 billion in the third quarter of 2026, 
      representing growth of 36% compared to the prior-year period. 
 
   --  TEVIMBRA (tislelizumab): Global sales totaled $243 million in the third 
      quarter of 2026, representing growth of 28% compared to the prior-year 
      period. 
 
   --  Amgen in-licensed products: Global sales totaled $167 million in the 
      third quarter of 2026, representing growth of 26% compared to the 
      prior-year period. 

Gross Margin as a percentage of global product sales for the third quarter of 2026 was 88%, compared to 86% in the prior-year period on a GAAP basis. The gross-margin percentage increased due to a proportionally higher sales mix of global BRUKINSA compared to other products in the Company's portfolio. Gross margin also benefited from productivity improvements resulting in lower costs for both BRUKINSA and TEVIMBRA, which was offset by a non-cash intangible asset impairment charge of $22 million associated with our decision to discontinue promotion of POBEVCY. On an adjusted basis, which does not include depreciation and amortization, or the impairment charge, gross margin as a percentage of product sales increased to 90%, from 86% in the comparable period of the prior year.

Operating Expenses

The following table summarizes operating expenses for the third quarter of 2026:

 
 
                           GAAP                             Non-GAAP 
                  ----------------------              -------------------- 
(unaudited, in 
thousands, 
except 
percentages)       Q3 2026     Q3 2025     % Change    Q3 2026    Q3 2025    % Change 
                  ----------  ----------  ----------  ----------  --------  ---------- 
Research and 
 development      $  660,784  $  523,662   26%        $  586,168  $445,904   31% 
Selling, general 
 and 
 administrative   $  593,460  $  528,998   12%        $  503,719  $434,484   16% 
                   ---------   ---------               ---------   ------- 
Total operating 
 expenses         $1,254,244  $1,052,660   19%        $1,089,887  $880,388   24% 
                   ---------   ---------               ---------   ------- 
 

The following table summarizes operating expenses for the year-to-date period ended September 30, 2026, and 2025:

 
 
                           GAAP                              Non-GAAP 
                  ----------------------              ---------------------- 
(unaudited, in 
thousands, 
except              Q3 YTD      Q3 YTD                  Q3 YTD      Q3 YTD 
percentages)         2026        2025      % Change      2026        2025      % Change 
                  ----------  ----------  ----------  ----------  ----------  ---------- 
Research and 
 development      $1,814,288  $1,530,445   19%        $1,586,022  $1,311,156   21% 
Selling, general 
 and 
 administrative   $1,741,771  $1,526,199   14%        $1,476,386  $1,271,650   16% 
                   ---------   ---------               ---------   --------- 
Total operating 
 expenses         $3,556,059  $3,056,644   16%        $3,062,408  $2,582,806   19% 
                   ---------   ---------               ---------   --------- 
 

Research and Development (R&D) Expenses increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to advancing early clinical programs into late stage and preclinical programs into the clinic.

Selling, General and Administrative (SG&A) Expenses increased for the third quarter of 2026 compared to the prior-year period on both a GAAP and adjusted basis due to continued investment to support commercial growth.

Net Income and Basic/Diluted Earnings Per Share

GAAP net income for the third quarter of 2026 was $385 million, an increase of $260 million over the prior-year period, primarily attributable to revenue growth and improved operating leverage. Adjusted net income was $539 million, an increase of $235 million over the prior-year period.

For the third quarter of 2026, basic and diluted earnings per share were $0.26 and $0.25 per share and $3.38 and $3.28 per American Depositary Share (ADS), respectively, compared to $0.09 and $0.08 per share and $1.13 and $1.09 per ADS in the prior-year period. On an adjusted basis, basic and diluted earnings per share was $0.36 and $0.35 per share and $4.74 and $4.59 per ADS, respectively, compared to $0.21 and $0.20 per share and $2.76 and $2.65 per ADS in the prior-year period.

Free Cash Flow for the third quarter of 2026 was $474 million, representing an increase of $119 million over the prior-year period.

For further details on BeOne's Third Quarter 2026 Financial Statements, please see BeOne's Quarterly Report on Form 10-Q for the third quarter of 2026 filed with the U.S. Securities and Exchange Commission.

Full Year 2026 Guidance

BeOne's financial guidance is summarized below:

 
                            Prior FY 2026 Guidance  Current FY 2026 
                                                    Guidance(1) 
Total revenue               $6.6B - $6.8B           $6.9B - $7.0B 
GAAP gross margin %         High-80% range          High-80% range 
GAAP operating expenses(2)  $4.8B - $5.0B           $4.9B - $5.0B 
(combined R&D and SG&A) 
GAAP operating income(2)    $1.0B - $1.1B           $1.2B - $1.3B 
Non-GAAP operating          $1.7B-$1.8B             $1.9B-$2.0B 
income(2,3) 
 
(1) Assumes November 1, 2026, foreign exchange rates. 
(2) Does not assume any potential new, material business development activity 
or unusual/non-recurring items. 
(3) Non-GAAP operating income is a financial measure that excludes from the 
corresponding GAAP measure costs related to share-based compensation, 
depreciation and amortization expense. Guidance assumes that Non-GAAP expenses 
track overall expense growth. 
 

BeOne's total revenue guidance for full year 2026 of $6.9 billion to $7.0 billion reflects performance through the third quarter and the Company's expectations for the remainder of the year. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth.

The Company is providing the following additional guidance on items impacting net income and earnings per ADS:

   --  Other income (expense): Estimated range of $25 million to $50 million 
      in expense, includes interest amortization from the Royalty Pharma 
      arrangement. 
 
   --  Income tax outlook: Earnings may provide sufficient positive evidence 
      to reverse certain valuation allowances in 2026, resulting in a material 
      tax benefit when recognized. The Company continues to evaluate and assess 
      the magnitude but expects the reversal will occur in the fourth quarter 
      of 2026. See Form 10-Q for additional updates. 
 
   --  Diluted ADS outstanding: The Company expects diluted ADSs outstanding 
      of approximately 118 million. 

Third Quarter 2026 Business Highlights

Core Marketed Products

BRUKINSA (zanubrutinib)

   --  Received U.S. Food and Drug Administration (FDA) Priority Review 
      designation for the Phase 3 MANGROVE filing 
 
   --  Completed Phase 3 MANGROVE regulatory submissions in the EU and China. 
 
 
   --  29 abstracts accepted for presentation at the American Society of 
      Hematology (ASH) 2026 Annual Meeting, including interim analysis results 
      from the Phase 3 MANGROVE study in first-line mantle cell lymphoma (MCL) 
      to be presented during the Plenary Scientific Session. 

BEQALZI (sonrotoclax)

   --  10 abstracts accepted for presentation at ASH 2026. 

TEVIMBRA (tislelizumab)

   --  Received Japan regulatory approval for the treatment of adult patients 
      with first-line nasopharyngeal cancer. 

ZIIHERA (zanidatamab) for which BeOne holds commercialization rights in select markets

   --  Presented Phase 3 survival data reinforcing benefit of 
      ZIIHERA-containing regimens in first-line HER2+ gastroesophageal 
      adenocarcinoma (GEA) at the European Society for Medical Oncology 
      Congress 2026 (ESMO 2026). 
 
   --  Received U.S. Food and Drug Administration (FDA) approval for 
      TEVIMBRA-based regimen for first-line HER2+ GEA. 

Select Clinical-Stage Programs

Hematology

   --  6 Tacabrutideg abstracts accepted for presentation at ASH 2026. 
 
   --  Tacabrutideg (BTK CDAC): Pivotal Phase 2 portion of CaDAnCe-101 met its 
      primary endpoint of overall response rate in patients with 
      relapsed/refractory chronic lymphocytic leukemia (CLL). 
 
   --  BG-75202 (KAT6 A/B inhibitor): First patient enrolled into monotherapy 
      cohort for the Phase 1 study for the treatment of adult patients with 
      acute myeloid leukemia. 

Gastrointestinal Cancers

   --  BGB-B2033 (GPC3x4-1BB bispecific antibody): 
 
          --  Updated data presented at ESMO 2026. 
 
          --  Received Orphan Drug Designation from the European Commission 
             and awarded Innovation Passport, enabling entry to the UK's 
             Innovative Licensing and Access Pathway, in hepatocellular 
             carcinoma $(HCC)$. 
 
 
 
   --  BG-85738 (RAS ONi): First patient enrolled in the Phase 1 study of 
      advanced solid tumors with RAS mutations. 

Lung Cancer

   --  BG-C477 (CEA ADC): 
 
          --  Disclosed first clinical data at ESMO 2026. 
 
          --  Received FDA Fast Track Designation for the treatment of 
             patients with advanced or metastatic CEA-high non-small cell lung 
             cancer whose disease has progressed following prior systemic 
             therapy. 
 
 
 
   --  BGB 58067 (MTA-cooperative PRMT5 inhibitor): Disclosed first clinical 
      data at ESMO 2026. 

Breast and Gynecological Cancers

   --  BG-C9074 (B7-H4 ADC): Initiated Starstone-301 Phase 3 study in 
      combination with bevacizumab for the treatment of adult patients with 
      first-line ovarian cancer in maintenance setting. 

Anticipated R&D Milestones

 
Programs                           Milestones                         Timing 
---------------------------------  ---------------------------------  -------- 
BRUKINSA                           Regulatory submission in Japan     Q4 2026 
                                   for the treatment of adult 
                                   patients with first-line MCL. 
TEVIMBRA                           China regulatory action for the 
                                   treatment of adult patients with    1H 2027 
                                   first-line HER2-positive GEA in 
                                   combination with ZIIHERA and 
                                   chemotherapy. 
ZIIHERA                            China regulatory action for the    1H 2027 
                                   treatment of adult patients with 
                                   first-line HER2-positive GEA in 
                                   combination with chemotherapy, 
                                   with or without TEVIMBRA. 
Tacabrutideg                       Phase 2 potential submission for   Mid 2027 
 (BGB-16673)                       the treatment of adult patients 
                                   with R/R CLL. 
                                   CaDAnCe-306: Phase 3 study         1H 2027 
                                   initiation for R/R CLL in 
                                   combination with BEQALZI 
                                   GroundBBreaker-301 Phase 3 study   Q4 2026 
                                   initiation in second-line or 
                                   later HCC. 
BGB-B2033                          GroundBBreaker-201 potentially     Q4 2026 
 (GPC3x4-1BB bispecific antibody)  pivotal single-arm Phase 2 study 
                                   initiation in second-line or 
                                   later HCC. 
                                   GroundBBreaker-302 pivotal Phase   1H 2027 
                                   3 study initiation in first-line 
                                   HCC. 
 

Corporate Updates

   --  Announced a multi-part collaboration with Revolution Medicines, 
      including a clinical collaboration to evaluate drug combinations 
      incorporating select clinical-stage oncology assets from BeOne with any 
      of Revolution Medicines' four clinical RAS(ON) inhibitors, and a separate 
      regional rights agreement granting BeOne exclusive development and 
      commercialization rights to these Revolution Medicines assets in select 
      Asian markets. 
 
   --  Announced a voluntary agreement with the U.S. Government to expand 
      access to innovative cancer medicines for American patients while 
      strengthening the Company's U.S manufacturing footprint. 
 
   --  Announced the renewal of a partnership with the BeOne Care Foundation 
      and The Max Foundation, a leading global health nonprofit organization, 
      to expand access to BRUKINSA for the treatment of adult patients with CLL 
      in low- and middle-income countries through 2028. 

BeOne's Earnings Results Webcast

The Company's earnings conference call for the third quarter 2026 will be broadcast via webcast at 8:00 a.m. ET on Thursday, November 5, 2026, and will be accessible through the Investors section of BeOne's website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: BeOne's continued rapid global growth and leadership in hematology; future catalysts for BeOne's business; BeOne's full year 2026 guidance; BeOne's expectations regarding certain valuation allowances; BeOne's expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical and regulatory developments and data readouts; and BeOne's plans, commitments, aspirations and goals under the caption "About BeOne." Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC"), as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this press release is as

of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne's financial guidance is based on estimates and assumptions that are subject to significant uncertainties.

 
                Condensed Consolidated Statements of Operations (U.S. GAAP) 
(Amounts in thousands of U.S. dollars, except for shares, American Depositary Shares (ADSs), 
                                per share and per ADS data) 
 
                               Three Months Ended                 Nine Months Ended 
                                  September 30,                      September 30, 
                        --------------------------------  ---------------------------------- 
                             2026             2025             2026             2025 
                         -------------    -------------    -------------    ------------- 
 
                                  (Unaudited)                        (Unaudited) 
Revenues 
   Product revenue, 
    net                 $    1,855,057   $    1,395,013   $    5,022,180   $    3,805,619 
   Other revenue                34,758           17,271           86,144           39,244 
                         -------------    -------------    -------------    ------------- 
      Total revenues         1,889,815        1,412,284        5,108,324        3,844,863 
Cost of sales - 
 products                      216,896          196,510          558,641          526,118 
                         -------------    -------------    -------------    ------------- 
Gross profit                 1,672,919        1,215,774        4,549,683        3,318,745 
Operating expenses: 
   Research and 
    development                660,784          523,662        1,814,288        1,530,445 
   Selling, general 
    and 
    administrative             593,460          528,998        1,741,771        1,526,199 
                         -------------    -------------    -------------    ------------- 
      Total operating 
       expenses              1,254,244        1,052,660        3,556,059        3,056,644 
                         -------------    -------------    -------------    ------------- 
Income from operations         418,675          163,114          993,624          262,101 
   Interest income              33,663           19,393           89,227           43,735 
   Interest expense            (42,407)         (16,364)        (115,033)         (31,361) 
   Other income 
    (expense), net                 429          (18,979)          14,216           (6,862) 
                         -------------    -------------    -------------    ------------- 
Income before income 
 taxes                         410,360          147,164          982,034          267,613 
Income tax expense              25,654           22,323          132,964           47,182 
                         -------------    -------------    -------------    ------------- 
Net income              $      384,706   $      124,841   $      849,070   $      220,431 
                         =============    =============    =============    ============= 
 
Earnings per share 
   Basic                $         0.26   $         0.09   $         0.58   $         0.16 
                         =============    =============    =============    ============= 
   Diluted              $         0.25   $         0.08   $         0.56   $         0.15 
                         =============    =============    =============    ============= 
Weighted-average 
 shares 
 outstanding--basic      1,478,074,394    1,432,801,699    1,457,134,424    1,410,497,062 
                         =============    =============    =============    ============= 
Weighted-average 
 shares 
 outstanding--diluted    1,524,954,790    1,488,750,354    1,511,972,953    1,465,535,004 
                         =============    =============    =============    ============= 
 
Earnings per American 
Depositary Share 
("ADS") 
   Basic                $         3.38   $         1.13   $         7.58   $         2.03 
                         =============    =============    =============    ============= 
   Diluted              $         3.28   $         1.09   $         7.30   $         1.96 
                         =============    =============    =============    ============= 
Weighted-average ADSs 
 outstanding--basic        113,698,030      110,215,515      112,087,263      108,499,774 
                         =============    =============    =============    ============= 
Weighted-average ADSs 
 outstanding--diluted      117,304,215      114,519,258      116,305,612      112,733,462 
                         =============    =============    =============    ============= 
 
 
       Select Condensed Consolidated Balance Sheet Data (U.S. GAAP) 
                  (Amounts in thousands of U.S. Dollars) 
 
                                                        As of 
                                           ------------------------------- 
                                            September 30,    December 31, 
                                                2026             2025 
                                           ---------------  -------------- 
                                             (unaudited)      (audited) 
Assets: 
Cash, cash equivalents and restricted 
 cash                                       $    5,866,314   $   4,609,647 
Accounts receivable, net                         1,092,535         865,080 
Inventories                                        807,922         608,227 
Property, plant and equipment, net               1,647,231       1,641,678 
Total assets                                $    9,875,925   $   8,188,573 
Liabilities and equity: 
Accounts payable                            $      496,879   $     479,035 
Accrued expenses and other payables              1,342,646       1,109,120 
R&D cost share liability                                --          64,345 
Sale of future royalty liability                   912,581         906,956 
Debt                                             1,074,081       1,019,206 
Total liabilities                                4,055,531       3,827,379 
Total equity                                $    5,820,394   $   4,361,194 
 
 
    Select Condensed Consolidated Statements of Cash Flows (U.S. GAAP) 
                  (Amounts in thousands of U.S. Dollars) 
 
                         Three Months Ended         Nine Months Ended 
                            September 30,              September 30, 
                      ------------------------  -------------------------- 
                         2026         2025         2026         2025 
                       ---------    ---------    ---------    --------- 
 
                            (unaudited)                (unaudited) 
Cash, cash 
 equivalents and 
 restricted cash at 
 beginning of 
 period               $5,280,674   $2,786,086   $4,609,647   $2,638,747 
   Net cash provided 
    by operating 
    activities           508,707      402,553    1,172,863      710,233 
   Net cash used in 
    investing 
    activities           (35,760)     (49,274)    (130,623)    (237,820) 
   Net cash provided 
    by financing 
    activities           102,194      961,272      164,772      962,520 
   Net effect of 
    foreign exchange 
    rate changes          10,499        9,905       49,655       36,862 
                       ---------    ---------    ---------    --------- 
      Net increase 
       in cash, cash 
       equivalents, 
       and 
       restricted 
       cash              585,640    1,324,456    1,256,667    1,471,795 
                       ---------    ---------    ---------    --------- 
Cash, cash 
 equivalents and 
 restricted cash at 
 end of period        $5,866,314   $4,110,542   $5,866,314   $4,110,542 
                       =========    =========    =========    ========= 
 

Note Regarding Use of Non-GAAP Financial Measures

BeOne provides certain non-GAAP financial measures, including Adjusted Cost of Sales- Product, Adjusted Operating Expenses, Adjusted Income from Operations, Adjusted Income Tax Expense, Adjusted Net Income, Adjusted Earnings Per Share, Free Cash Flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP financial measures are intended to provide additional information on BeOne's operating performance. Adjustments to BeOne's GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Non-GAAP adjustments are tax effected to the extent there is U.S. GAAP current tax expense. The Company currently records a valuation allowance on its net deferred tax assets, so there is no net impact recorded for deferred tax effects. BeOne maintains an established non-GAAP policy that guides the determination of what costs will be excluded in non-GAAP financial measures and the related protocols, controls and approval with respect to the use of such measures. BeOne believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of BeOne's operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of BeOne's historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeOne's management uses for planning and forecasting purposes and measuring BeOne's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by BeOne may be calculated differently

from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

 
     RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES 
(Amounts in thousands of U.S. Dollars, except for per share and per ADS 
                                 data) 
                              (unaudited) 
 
                      Three Months Ended         Nine Months Ended 
                        September 30,              September 30, 
                   ------------------------  -------------------------- 
                      2026         2025         2026         2025 
                    ---------    ---------    ---------    --------- 
 
Reconciliation 
of GAAP to 
adjusted cost of 
sales - 
products: 
GAAP cost of 
 sales - 
 products          $  216,896   $  196,510   $  558,641   $  526,118 
Less: 
 Depreciation           5,596        4,261       15,442       10,195 
Less: 
 Amortization of 
 intangibles           23,598        1,537       26,932        8,459 
Less: Other                --           --           --          893 
                    ---------    ---------    ---------    --------- 
Adjusted cost of 
 sales - 
 products          $  187,702   $  190,712   $  516,267   $  506,571 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted 
research and 
development: 
GAAP research and 
 development       $  660,784   $  523,662   $1,814,288   $1,530,445 
Less: Share-based 
 compensation 
 cost                  56,474       58,839      168,866      164,998 
Less: 
 Depreciation          18,142       18,919       59,400       54,291 
                    ---------    ---------    ---------    --------- 
Adjusted research 
 and development   $  586,168   $  445,904   $1,586,022   $1,311,156 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted 
selling, general 
and 
administrative: 
GAAP selling, 
 general and 
 administrative    $  593,460   $  528,998   $1,741,771   $1,526,199 
Less: Share-based 
 compensation 
 cost                  76,143       81,947      224,566      221,792 
Less: 
 Depreciation          13,582       12,550       40,769       32,712 
Less: 
 Amortization of 
 intangibles               16           17           50           45 
                    ---------    ---------    ---------    --------- 
Adjusted selling, 
 general and 
 administrative    $  503,719   $  434,484   $1,476,386   $1,271,650 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted 
operating 
expenses: 
GAAP operating 
 expenses          $1,254,244   $1,052,660   $3,556,059   $3,056,644 
Less: Share-based 
 compensation 
 cost                 132,617      140,786      393,432      386,790 
Less: 
 Depreciation          31,724       31,469      100,169       87,003 
Less: 
 Amortization of 
 intangibles               16           17           50           45 
                    ---------    ---------    ---------    --------- 
Adjusted 
 operating 
 expenses          $1,089,887   $  880,388   $3,062,408   $2,582,806 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted income 
from 
operations: 
GAAP income from 
 operations        $  418,675   $  163,114   $  993,624   $  262,101 
Plus: Share-based 
 compensation 
 cost                 132,617      140,786      393,432      386,790 
Plus: 
 Depreciation          37,320       35,730      115,611       97,198 
Plus: 
 Amortization of 
 intangibles           23,614        1,554       26,982        8,504 
Plus: Other                --           --           --          893 
                    ---------    ---------    ---------    --------- 
Adjusted income 
 from operations   $  612,226   $  341,184   $1,529,649   $  755,486 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted income 
tax expense: 
GAAP income tax 
 expense           $   25,654   $   22,323   $  132,964   $   47,182 
Plus: Discrete 
 tax items             11,527          926      (41,847)       9,663 
Plus: Income tax 
 effect of 
 non-GAAP 
 adjustments           27,995       17,044       68,668       45,747 
                    ---------    ---------    ---------    --------- 
Adjusted income 
 tax expense       $   65,176   $   40,293   $  159,785   $  102,592 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted net 
income: 
GAAP net income    $  384,706   $  124,841   $  849,070   $  220,431 
Plus: Share-based 
 compensation 
 expenses             132,617      140,786      393,432      386,790 
Plus: 
 Depreciation          37,320       35,730      115,611       97,198 
Plus: 
 Amortization of 
 intangibles           23,614        1,554       26,982        8,504 
Plus: Other                --           --           --          893 
Plus: Impairment 
 of equity 
 investments               --       18,722           --       34,216 
Plus: Discrete 
 tax items            (11,527)        (926)      41,847       (9,663) 
Plus: Income tax 
 effect of 
 non-GAAP 
 adjustments(1)       (27,995)     (17,044)     (68,668)     (45,747) 
                    ---------    ---------    ---------    --------- 
Adjusted net 
 income            $  538,735   $  303,663   $1,358,274   $  692,622 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted EPS - 
basic 
GAAP earnings per 
 share - basic     $     0.26   $     0.09   $     0.58   $     0.16 
Plus: Share-based 
 compensation 
 expenses                0.09         0.10         0.27         0.27 
Plus: 
 Depreciation            0.03         0.02         0.08         0.07 
Plus: 
 Amortization of 
 intangibles             0.02         0.00         0.02         0.01 
Plus: Other              0.00         0.00         0.00         0.00 
Plus: Impairment 
 of equity 
 investments             0.00         0.01         0.00         0.02 
Plus: Discrete 
 tax items              (0.01)        0.00         0.03        (0.01) 
Plus: Income tax 
 effect of 
 non-GAAP 
 adjustments(1)         (0.02)       (0.01)       (0.05)       (0.03) 
                    ---------    ---------    ---------    --------- 
Adjusted earnings 
 per share - 
 basic             $     0.36   $     0.21   $     0.93   $     0.49 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted EPS - 
diluted 
GAAP earnings per 
 share - diluted   $     0.25   $     0.08   $     0.56   $     0.15 
Plus: Share-based 
 compensation 
 expenses                0.09         0.09         0.26         0.26 
Plus: 
 Depreciation            0.02         0.02         0.08         0.07 
Plus: 
 Amortization of 
 intangibles             0.02         0.00         0.02         0.01 
Plus: Other              0.00         0.00         0.00         0.00 
Plus: Impairment 
 of equity 
 investments             0.00         0.01         0.00         0.02 
Plus: Discrete 
 tax items              (0.01)        0.00         0.03        (0.01) 
Plus: Income tax 
 effect of 
 non-GAAP 
 adjustments(1)         (0.02)       (0.01)       (0.05)       (0.03) 
                    ---------    ---------    ---------    --------- 
Adjusted earnings 
 per share - 
 diluted           $     0.35   $     0.20   $     0.90   $     0.47 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted 
earnings per ADS 
- basic 
GAAP earnings per 
 ADS - basic       $     3.38   $     1.13   $     7.58   $     2.03 
Plus: Share-based 
 compensation 
 expenses                1.17         1.28         3.51         3.56 
Plus: 
 Depreciation            0.33         0.32         1.03         0.90 
Plus: 
 Amortization of 
 intangibles             0.21         0.01         0.24         0.08 
Plus: Other              0.00         0.00         0.00         0.01 
Plus: Impairment 
 of equity 
 investments             0.00         0.17         0.00         0.32 
Plus: Discrete 
 tax items              (0.10)       (0.01)        0.37        (0.09) 
Plus: Income tax 
 effect of 
 non-GAAP 
 adjustments(1)         (0.25)       (0.15)       (0.61)       (0.42) 
                    ---------    ---------    ---------    --------- 
Adjusted earnings 
 per ADS - basic   $     4.74   $     2.76   $    12.12   $     6.38 
                    =========    =========    =========    ========= 
 
Reconciliation 
of GAAP to 
adjusted 
earnings per ADS 
- diluted 
GAAP earnings per 
 ADS - diluted     $     3.28   $     1.09   $     7.30   $     1.96 
Plus: Share-based 
 compensation 
 expenses                1.13         1.23         3.38         3.43 
Plus: 
 Depreciation            0.32         0.31         0.99         0.86 
Plus: 
 Amortization of 
 intangibles             0.20         0.01         0.23         0.08 
Plus: Other              0.00         0.00         0.00         0.01 
Plus: Impairment 
 of equity 
 investments             0.00         0.16         0.00         0.30 
Plus: Discrete 
 tax items              (0.10)       (0.01)        0.36        (0.09) 
Plus: Income tax 
 effect of 
 non-GAAP 
 adjustments(1)         (0.24)       (0.15)       (0.59)       (0.41) 
                    ---------    ---------    ---------    --------- 
Adjusted earnings 
 per ADS - 
 diluted           $     4.59   $     2.65   $    11.68   $     6.14 
                    =========    =========    =========    ========= 
Tax effect of Non-GAAP adjustments is based on the statutory tax rate 
in the relevant tax jurisdiction. Please note that the Company 
currently records a valuation allowance on its net deferred tax assets, 
so there is no net impact recorded for deferred tax effects. 
 
 
                Three Months Ended       Nine Months Ended 
                  September 30,            September 30, 
               --------------------  ------------------------- 
                 2026       2025        2026         2025 
                -------    -------    ---------    -------- 
 
Free Cash 
Flow 
(Non-GAAP): 
Net cash 
 provided by 
 operating 
 activities 
 (GAAP)        $508,707   $402,553   $1,172,863   $ 710,233 
Less: 
 Purchases of 
 property, 
 plant and 
 equipment      (35,175)   (48,084)    (103,440)   (148,317) 
                -------    -------    ---------    -------- 
Free Cash 
 Flow 
 (Non-GAAP)    $473,532   $354,469   $1,069,423   $ 561,916 
                =======    =======    =========    ======== 
 
 
Reconciliation of GAAP Operating Income Guidance 
to Non-GAAP 
Operating Income Guidance for Full Year 2026 
                                                        (Unaudited) 
 
GAAP operating income                             1,200,000  --  1,300,000 
Plus: Adjustments to arrive at Non-GAAP(1)          700,000  --    700,000 
                                                  ---------      --------- 
Non-GAAP operating income                         1,900,000  --  2,000,000 
                                                  =========      ========= 
The non-GAAP adjustments are based on actual results through the first 
nine months of 2026 and best available information at this time related to 
similar items for the remainder of the year. 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20261105790053/en/

 
    CONTACT:    Investor Contact 

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Meredith Ferguson

+1 216-338-3797

media@beonemed.com

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment